> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CDER Approved 50 Novel Products Last Year
- URL: https://www.fdaweb.com/cder-approved-50-novel-products-last-year/
- Published: 2025-01-06T12:00:00.000Z
- Updated: 2026-09-14T14:50:07.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158431

CDER approved 50 novel products in 2024, which was five (9%) less than the 55 products approved in 2023 and well above the 10-year rolling average of almost 46 approvals. Oncology approvals remained the top therapeutic category last year, with 15 (30%) novel approvals, according to the [journal *Nature*](https://www.nature.com/articles/d41573-025-00001-5?source=email). Dermatology and non-malignant hematology were tied for second, with six (12%) approvals apiece. The agency also signed off on five (10%) new cardiology agents, while neurology and infectious diseases posted lower approval numbers than in recent years, it says. *Nature* also includes a rundown of 10 notable CBER approvals last year.